3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Dexamethasone
33
Lenalidomide
14
pomalidomide
12
daratumumab
12
Bortezomib
12
venetoclax
7
Cyclophosphamide
7
isatuximab
6
Therapeutics
6
trametinib
4
carfilzomib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
fludarabine
3
dabrafenib
3
Vemurafenib
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Drug Therapy
3
Denosumab
3
Ciprofloxacin
3
Calcium Dobesilate
3
ridaforolimus
2
pembrolizumab
2
molibresib
2
liposomal amphotericin B
2
fludarabine phosphate
2
cobimetinib
2
afuresertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Clavulanic Acid
×
Plasma cell
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled